Figure 5. Fuz expression was associated with its promoter methylation level in ESCA and LUAD tumor samples. (A) Fuz methylation data obtained from Firebrowse database indicates that Fuz mRNA level was negatively associated with its promoter methylation level in various types of cancer. Three methylation sites (cg11398523, cg21712019 and cg22708738) were highlighted, and these sites reside within or close to a potential CpG island (Fuz+117/+347CpG) in Fuz+68/+574 promoter region. The CpG island Fuz+117/+347CpG was predicted using MethPrimer software (https://www.urogene.org/cgi-bin/methprimer/methprimer.cgi) . (B, C) Fuz mRNA level negatively correlates with the methylation at cg11398523 site within Fuz promoter in ESCA (B) and HNSC (C) patient samples. (D) A negative correlation between Fuz expression and Fuz promoter methylation level (at cg22708738 site) was identified in LUAD patient samples. (E) Treatment of 5-Azacytidine upregulated Fuz transcript level in esophageal carcinoma KYSE150 and KYSE510 cell lines. (F) Fuz transcript level was increased upon treatment of 5-Azacytidine in lung adenocarcinoma H4006 and NCI-H1975 cell lines. n = 3 biological replicates. Each n represents an independent preparation of cell RNA samples. Error bars represent S.E.M.. Statistical analysis was performed using two-tailed unpaired Student’s t-test. * denotes p < 0.05.